Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentric, Rand., D-b, Pbo Controlled Clinical Trial to Evaluate the Efficacy and the Safety of the Thromboprophylaxis With Bemiparin 3,500 IU/d for 28 Days Compared to 8 Days, in Patients Undergoing Oncological Abdominal/ Pelvic Surgery

NCT00219973 is registered in ClinicalTrials.gov with Rovi Pharmaceuticals Laboratories as lead sponsor.

NCT NCT00219973
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219973 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentric, Rand., D-b, Pbo Controlled Clinical Trial to Evaluate the Efficacy and the Safety of the Thromboprophylaxis With Bemiparin 3,500 IU/d for 28 Days Compared to 8 Days, in Patients Undergoing Oncological Abdominal/ Pelvic Surgery
Lead sponsor
Rovi Pharmaceuticals Laboratories
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2005
Completion date
April 30, 2009
Enrollment
526 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, venous thromboembolism